

Note: the clinical conditions included in this table are placed here as a way of separating the conditions into two tables and does not imply a formal definition of “joint health conditions”

HCU= Health care utilization

- I. Rheumatoid arthritis flare domains: pain, function, swollen joints, tender joints, patient global, physician global, laboratory tests, fatigue, stiffness, participation, self-management (Bykerk 2014)
- II. Ankylosing spondylitis: Core domains vary depending on focus of study; domains that must be measured in disease modification trials are an extension of the mandatory domains to be measured in symptom modification trials.
- III. Mandatory in trials of disease modifying drugs.
- IV. For example, uveitis, inflammatory bowel disease, psoriasis
- V. For example, arthritis, enthesitis, dactylitis
- VI. If impact of symptoms is specified, these would fall under Impact
- VII. Their assessment includes both swelling and pain
- VIII. Mandatory in specific circumstances: hand mobility mandatory in clinical trials of structure modification and observational studies
- IX. Mandatory in specific circumstances: Juvenile Idiopathic Arthritis has domains that will be elicited if there are specific circumstances (i.e., eye involvement invokes assessment of uveitis). See reference for more complete list.
- X. Radiographic damage measured in studies >1 year
- XI. Mandatory in specific circumstances: joint imaging mandatory in trials assessing interventions expected to change structure.
- XII. Acute phase proteins were named for systemic inflammation
- XIII. Reporting of adverse events (including death) is mandatory in trials and death is a core area in OMERACT Filter 2.

References

1. Wolfe F, Lasserre M, van der Heijde D, et al.: Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology, *J Rheumatol* 1999. 26:484–489.
2. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d’Agostino MA, et al. Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. *J Clin Epidemiol* 2014; 67: 745-753
3. Boers M, Beaton D, Shea B, Maxwell LJ, Bartlett S, Bingham III C, et al. OMERACT Filter 2.1: elaboration of the conceptual framework for outcome measurement in health intervention studies. *J Rheumatol.* 2019. 46(8):1021–1027
4. Boers M, Tugwell P, Felson DT, van Riel PLCM, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology Core Endpoints for Symptom Modifying Antirheumatic Drugs in Rheumatoid Arthritis Clinical Trials. *J Rheumatol* 1994;(suppl 41) 21:86-9
5. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B. et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum.* 1993 Jun;36:729-40.
6. Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al. Patient Perspective: Fatigue as a Recommended Patient Centered Outcome Measure in Rheumatoid Arthritis. *J Rheumatol* 2007;34:1174–7
7. Bykerk VP, Lie E, Bartlett SJ, Alten R, Boonen A, Christensen R, et al. Establishing a Core Domain Set to Measure Rheumatoid Arthritis Flares: Report of the OMERACT 11 RA Flare Workshop. *J Rheumatol* 2014; 41:799–809
8. Orbai AM, de Wit M, Mease P, Callis Duffin K, Elmamoun M, Tillett W, et al. Updating the Psoriatic Arthritic Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. *J Rheumatol* 2017; 44:1522–1528
9. Schumacher HR, Taylor W, Edwards L, Grainger R, Schesinger N, Dalbeth N, et al. Outcome Domains for Studies of Acute and Chronic Gout. *J Rheumatol* 2009;36:2342–5
10. Smith TO, Hawker GA, Hunter DJ, March LM, Boers M, Shea BJ, et al. The OMERACT-OARSI core domain set for measurement in clinical trials of hip and/or knee osteoarthritis. *J Rheumatol* 2019. Aug;46(8):981-989. doi: 10.3899/jrheum.181194
11. Kloppenburg M, Bøyesen P, Willemsen Visser A, Haugen IK, Boers M, Boonen A, et al. Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. *J Rheumatol* 2015;42:2190-2197
12. Navarro-Compán, V., Boel, A., Boonen, A, Mease, P., Landewé, R., Kiltz, U, et al. The ASAS-OMERACT core domain set for axial spondyloarthritis. *Seminars in arthritis and rheumatism*, 2021, Vol.51 (6), p.1342-1349.
<https://doi.org/10.1016/j.semarthrit.2021.07.021>
13. Mackie SL, Twohig H, Neill LM, Harrison E, Shea B, Black RJ, et al. The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. *J Rheumatol* 2017;44:1515-1521
14. Ramiro S, Page M, Whittle S, Huang H, Verhagen A, Beaton D, et al. The OMERACT core domain set for clinical trials of shoulder disorders. *J Rheumatol.* 2019;46:969–75; doi:10.3899/jrheum.181070
15. Morgan E, Munro J, Horonjeff J, Shea B, Feldman B, Bingham III C, et al. Establishing an updated core domain set for studies in juvenile idiopathic arthritis: a report from the OMERACT 2018 JIA Workshop. *J Rheumatol.* 2019 Aug;46(8):1006-1013. doi: 10.3899/jrheum.181088